Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis

Vaccine

Volumn 32, Issue 43, 2014, Pages 5681-5689

  Cappellano, Giuseppe ^a   Woldetsadik, Abiy Demeke ^a   Orilieri, Elisabetta ^a   Shivakumar, Yogesh ^a   Rizzi, Manuela ^a   Carniato, Fabio ^a   Gigliotti, Casimiro Luca ^a   Boggio, Elena ^a   Clemente, Nausicaa ^a   Comi, Cristoforo ^b   Dianzani, Chiara ^c   Boldorini, Renzo ^a   Chiocchetti, Annalisa ^a   Renò, Filippo ^a   Dianzani, Umberto ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NONE

Author keywords

Interleukin 10; PLGA; TREG; Tolerogenic vaccine

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; MYELIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; POLYGLACTIN; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN 10; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BRAIN; CD3+ T LYMPHOCYTE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIGHT SCATTERING; MCF 7 CELL LINE; MOUSE; MTT ASSAY; NANOENCAPSULATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTE; SCANNING ELECTRON MICROSCOPE; SCANNING ELECTRON MICROSCOPY; SPLEEN LYMPHOCYTE; SUSTAINED DRUG RELEASE; VACCINATION; ZETA POTENTIAL; ANIMAL; C57BL MOUSE; CYTOLOGY; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; SECRETION (PROCESS); SPLEEN; T LYMPHOCYTE;

ANIMALS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-17; LACTIC ACID; MCF-7 CELLS; MICE, INBRED C57BL; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NANOPARTICLES; POLYGLYCOLIC ACID; RECOMBINANT PROTEINS; SPLEEN; T-LYMPHOCYTES; VACCINATION;

EID: 84908401417     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.016     Document Type: Article

References (41)

1. Platten M., Steinman L. Multiple sclerosis: trapped in deadly glue. Nat Med 2005, 11:252-253.
2. Hsieh C.S., Zheng Y., Liang Y., Fontenot J.D., Rudensky A.Y. An intersection between the self-reactive regulatory and non regulatory T cell receptor repertoires. Nat Immunol 2006, 7:401-410.
3. + regulatory T cells. Int Immunol 2004, 16:249-256.
4. + T cells. J Immunol 2004, 173:6526-6531.
5. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002, 3:237-243.
6. Huss D.J., Winger R.C., Peng H., Yang Y., Racke M.K., Lovett-Racke A.E. TGF-beta enhances effector Th1 cell activation but promotes self-regulation via IL-10. J Immunol 2010, 184:5628-5636.
7. Yan Y., Zhang G.X., Gran B., Fallarino F., Yu S., Li H., et al. IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol 2010, 185:5953-5961.
8. Tang Q., Bluestone J.A. Regulatory T cell physiology and application to treat autoimmunity. Immunol Rev 2005, 212:217-237.
9. Ozdemir C., Kucuksezer U.C., Akdis M., Akdis C.A. Specific immunotherapy and turning off the T cell: how does it work?. Ann Allergy Asthma Immunol 2011, 107:381-392.
10. Lutterotti A., Sospedra M., Martin R. Antigen-specific therapies in MS - current concepts and novel approaches. J Neurol Sci 2008, 274:18-22.
11. Badawi A.H., Siahaan T.J. Immune modulating peptides for the treatment and suppression of multiple sclerosis. Clin Immunol 2012, 144:127-138.
12. Johnson D., Hafler D.A., Fallis R.J., Lees M.B., Brady R.O., Quarles R.H., et al. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol 1986, 13:99-108.
13. Smith C.E., Miller S.D. Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J Autoimmun 2006, 27:218-231.
14. Tsai C.Y., Chow N.H., Ho T.S., Lei H.Y. Intracerebral injection of myelin basic protein (MBP) induces inflammation in brain and causes paraplegia in MBP-sensitized B6 mice. Clin Exp Immunol 1997, 109:127-133.
15. Karpus W.J., Kennedy K.J., Smith W.S., Miller S.D. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide. J Neurosci Res 1996, 45:410-423.
16. Devaux B., Enderlin F., Wallner B., Smilek D.E. Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide. J Neuroimmunol 1997, 75:169-173.
17. Ho P.P., Fontoura P., Platten M., Sobel R.A., DeVoss J.J., Lee L.Y., et al. A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune disease. J Immunol 2005, 175:6226-6234.
18. Steinman L. Inverse vaccination, the opposite of Jenner's concept, for therapy of autoimmunity. J Intern Med 2010, 267:441-451.
19. Bar-Or A., Vollmer T., Antel J., Arnold D.L., Bodner C.A., Campagnolo D., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol 2007, 64:1407-1415.
20. Garren H., Robinson W.H., Krasulová E., Havrdová E., Nadj C., Selmaj K., et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008, 63:611-620.
21. Houchin M.L., Topp E.M. Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms. J Pharm Sci 2008, 97:2395-2404.
22. Jiang W., Gupta R.K., Deshpande M.C., Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev 2005, 57:391-410.
23. Leleux J., Roy K. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv Healthc Mater 2013, 2:72-94.
24. Keijzer C., Slütter B., van der Zee R., Jiskoot W., van Eden W., Broere F. PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. PLoS ONE 2011, 6:e26684.
25. Getts D.R., Martin A.J., McCarthy D.P., Terry R.L., Hunter Z.N., Yap W.T., et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol 2012, 30:1217-1224.
26. Zhou X., Liu B., Yu X., Zha X., Zhang X., Wang X., et al. Controlled release of PEI/DNA complexes from PLGA microspheres as a potent delivery system to enhance immune response to HIV vaccine DNA prime/MVA boost regime. Eur J Pharm Biopharm 2008, 68:589-595.
27. + T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'. Int Immunol 2008, 20:577-589.
28. + regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. J Neuroinflamm 2012, 9:139.
29. Semete B., Booysen L., Lemmer Y., Kalombo L., Katata L., Verschoor J., et al. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomedicine 2010, 6:662-671.
30. Nicolete R., dos Santos D.F., Faccioli L.H. The uptake of PLGA micro or nanoparticles by macrophages provokes distinct in vitro inflammatory response. Int Immunopharmacol 2011, 11:1557-1563.
31. Look M., Saltzman W.M., Craft J., Fahmy T.M. The nanomaterial-dependent modulation of dendritic cells and its potential influence on therapeutic immunosuppression in lupus. Biomaterials 2014, 35:1089-1095.
32. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:870-875.
33. Cannella B., Gao Y.L., Brosnan C., Raine C.S. IL-10 fails to abrogate experimental autoimmune encephalomyelitis. J Neurosci Res 1996, 45:735-746.
34. Peine K.J., Guerau-de-Arellano M., Lee P., Kanthamneni N., Severin M., Probst G.D., et al. Treatment of experimental autoimmune encephalomyelitis by codelivery of disease associated peptide and dexamethasone in acetalated dextran microparticles. Mol Pharm 2014, 11:828-835. 10.1021/mp4005172.
35. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. Encephalitogenic potential of the myelin basic protein peptide (aa 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
36. + regulatory T cells. J Mol Cell Biol 2014, 6:81-92.
37. reg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. Eur J Immunol 2009, 39:3423-3435.
38. Blank F., Stumbles P.A., Seydoux E., Holt P.G., Fink A., Rothen-Rutishauser B., et al. Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes. Am J Respir Cell Mol Biol 2013, 49:67-77.
39. Odoardi F., Sie C., Streyl K., Ulaganathan V.K., Schläger C., Lodygin D., et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488:675-679.
40. Lutterotti A., Yousef S., Sputtek A., Stürner K.H., Stellmann J.P., Breiden P., et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med 2013, 5:188ra75.
41. Kaushansky N., Kerlero de Rosbo N., Zilkha-Falb R., Yosef-Hemo R., Cohen L., et al. 'Multi-epitope targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptides. PLoS ONE 2011, 6:e27860.